Healthcare Without the Hold Music -- TxtSquad Leads the Shift
ST. JOHN'S, NL, May 27, 2025 /CNW/ - TxtSquad, an AI-powered patient engagement platform, is expanding its impact through a new partnership with the Coordinated Accessible National (CAN) Health Network to modernize communication between healthcare providers and patients.
As part of this initiative, TxtSquad is launching a pilot with NL Health Services in its bariatric surgery unit to explore how improved messaging and virtual care tools can enhance post-operative care and patient outcomes.
"Our mission is simple - improve healthcare accessibility," said Josh Taylor, CEO of TxtSquad.
"We make it easy for patients to reach their care teams—whether by secure text, voice, or video—without hold music, phone tag, or app downloads."
"This kind of access doesn't just improve the patient experience—it also frees up time for healthcare staff and improves outcomes," said Taylor.
This new initiative builds on momentum from a successful pilot in 10 community care clinics across Newfoundland and Labrador, where TxtSquad reduced no-show rates by up to 80%, increased patient satisfaction, and significantly cut call volumes.
TxtSquad's platform integrates with existing phone systems to offer secure two-way texting, phone wraparounds like call queues and voicemail, and AI agents for scheduling, reminders, follow-ups, and quality assurance.
It also enables AI-assisted phone and video interactions that transcribe and simplify virtual care—while delivering valuable operational insights. The platform is fully compliant with North American healthcare privacy regulations.
Visit www.txtsquad.com to learn how your clinic or healthcare organization can eliminate phone tag and put patients first.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
an hour ago
- Cision Canada
Reklaim Expands 'Protect' to Include California Opt-Outs, Ad Tech Removal, and Family Protection
Subscribers' data is now automatically removed from California-registered data brokers, as well as enterprise and DSP platforms TORONTO, June 20, 2025 /CNW/ - Reklaim Ltd. (TSXV: MYID) (OTC: MYIDF) ("Reklaim" or the "Company"), a leader in consumer data privacy and compliant data monetization, today announced a significant update to Reklaim Protect, its privacy subscription service that helps users shrink their digital footprint. With this latest release, Reklaim Protect now automatically removes subscriber data from companies listed in California's official data broker registry, as well as enterprise data platforms and demand-side platforms (DSP s) used in digital advertising. These new capabilities further strengthen Reklaim's position as a privacy-first alternative for consumers who want to opt out of the data economy and reduce the availability of their information for sale, targeting, or unauthorized use. "Removing your data from these platforms is about cutting off the source," said Neil Sweeney, Founder and CEO of Reklaim. "Brokers, fraudsters, and bad actors all rely on the same data supply to power their models. If you don't proactively reduce your footprint, your information remains exposed and in circulation. By integrating the California registry, we're cutting subscribers off from one of the largest data pipelines in the world." Key Features of Reklaim Protect (V2) California Data Broker Registry Opt-Out Reklaim subscribers' data is now automatically removed from data brokers listed in California's official registry, the largest of its kind in the world, with a single digital signature inside the Reklaim app. This step leverages state privacy laws to disconnect consumers from some of the most active and persistent data sellers in the U.S. View the official registry ➝ Enterprise & DSP Data Removal Reklaim now facilitates opt-outs from enterprise data platforms and demand-side platforms (DSPs) used by advertisers to profile and target consumers, helping reduce unwanted surveillance and behavioural tracking. Family-Wide Monitoring Protect Subscribers, who are also members of Reklaim Rewards, can also monitor up to 10 verified email addresses for dark web breaches, extending protection to family members and close contacts. These enhancements build on the original features of Reklaim Protect, which include: Reklaim Protect is available to Reklaim subscribers in Canada and the United States, offering a 14-day free trial and ongoing access for just $1/month or $10/year. The service is fully integrated into the Reklaim mobile and web app experience.
Cision Canada
3 hours ago
- Cision Canada
LG ANNOUNCES CANADIAN PRICING AND AVAILABILITY OF 2025 TV LINEUP Français
LG 2025 OLED and QNED TVS Deliver Exceptional Picture Quality, Enhanced Brightness, Incredible Gaming Performance and AI Personalization TORONTO, June 20, 2025 /CNW/ - Today, LG Electronics Canada (LG) announced Canadian pricing and availability of its 2025 media entertainment solutions lineup, which includes its industry-leading, LG OLED evo TV lineup and the QNED series – a premium LCD TV lineup that incorporates key innovations, such as advanced AI capabilities and wireless convenience. LG is also enhancing its lifestyle category with the LG StanbyME 2 – a versatile and high-quality entertainment solution. LG OLED evo TV Lineup As the global leader in OLED TV innovation for 12 consecutive years 1, LG continues to deliver cutting-edge technology that meets evolving consumer preferences. The LG 2025 OLED evo lineup enhances the home entertainment experience with the latest AI-driven technology and AI-powered personalization through webOS. LG OLED evo G5 Powered by the alpha 11 AI Processor 4K Gen2, the LG OLED evo G5 boasts a 45% increase in brightness compared to its predecessor, the LG OLED evo G4, thanks to Brightness Booster Ultimate technology 2 and AI-driven picture enhancements. The G5 delivers stellar picture quality with enhanced brightness. It also features 'Perfect Black' and 'Perfect Colour' Certifications, 3 ensuring deeper blacks and more vibrant, accurate colours for an unmatched viewing experience. The G5 offers a personalized and convenient user experience through its webOS 25 smart platform and multiple AI capabilities. It also supports Filmmaker Mode with Ambient Light Compensation, Dolby Vision™ and Dolby Atmos®, 4 AI Sound Pro for immersive audio, as well as gaming features including 4K, 165Hz VRR, NVIDIA G-SYNC and AMD FreeSync Premium. The LG OLED evo G5 series features a one wall design with narrow bezels and flush to the wall mounting, or optional stand, and is an ideal choice for both cinematic viewing and gaming. It is available in five screen sizes (55/65/77/83/97-inch) with an MSRP starting at $3,099.99. LG OLED evo C5 The C5 series offers a captivating home entertainment experience with its remarkable picture and audio quality, boasting 'Perfect Black' and 'Perfect Colour' Certifications, 3 along with Brightness Booster technology 5 powered by the alpha 9 AI Processor Gen 8. This series also supports Dolby Vision and Dolby Atmos®, 4 utilizing AI Picture Pro and AI Sound Pro to refine visuals and create virtual 11.1.2 channel audio, while the AI Picture/Sound Wizard customizes settings based on individual preferences. Gamers will appreciate features including 4K at 144Hz, minimal input lag, VRR support and VESA's ClearMR 9000 certification for smooth visuals, all within an ultra-slim design that seamlessly integrates into almost any space. The LG OLED evo C5 TV is available in six screen sizes (42/48/55/65/77/83-inch) and has an MSRP starting at $1,699.99. LG OLED evo B5 The LG OLED B5 combines visual excellence with compelling gaming performance. With 'Perfect Black' and 'Perfect Colour' technology 3 on over 8.3 million self-lit smart pixels powered by the alpha 8 AI Processor Gen2 processor, the LG OLED B5 series is designed to create an incredible viewing experience. Like other LG OLED models, the B5 supports Dolby Vision®, Dolby Atmos®, HDR10 Pro and FILMAKER MODE™. For dynamic action and fast-paced gaming, the B5 series delivers a suite of premium gaming features, including NVIDIA G-Sync, AMD FreeSync Premium & VRR and up to 120 Hz refresh rate. Users can enjoy the B5's gaming features – no console needed – with multiple cloud gaming apps including NVIDIA GeForce NOW, and more. The 2025 B-series also leverages advanced AI features that understand and adapt to individual audio and visual preferences. By analyzing over 1.6 billion image settings and 40 million sound profiles, the AI Picture & Sound Wizard develops a personalized viewing experience tailored to the user. This experience is enhanced with the use of the LG AI Magic Remote which allows for quick and easy access to TV controls via the new AI button. AI Welcome greets users by name and provides tailored recommendations based on their preferences and viewing habits, while AI Voice ID adds convenience by recognizing individual voices, automatically switching profiles and delivering content suggestions that match personal tastes. The LG OLED evo B5 TV is available in five screen sizes (48/55/65/77/83-inch) and has an MSRP starting at $1,699.99. QNED TV Lineup Marking a significant leap forward for LCD TVs, LG's new QNED evo TVs inherit the differentiated value of LG OLED, along with various colour solutions, Mini LED technology, the latest α (Alpha) AI processor, top-tier gaming performance and the versatile award-winning webOS platform. Certified by Intertek for achieving 100 percent colour volume 5, these cutting-edge TVs reproduce rich, true-to-life colours in both bright and dark environments. With the company's proprietary Dynamic QNED Colour solution, which replaces quantum dot technology, viewers can expect outstanding depth, clarity and precision regardless of lighting conditions. LG QNED evo AI (QNED9M) The LG QNED9M, is LG's first QNED TV featuring LG's True Wireless 4K technology. Users can enjoy high-definition wireless 4K 144Hz connectivity without compromising on picture quality or experiencing delays, moving beyond the limitations of traditional wired connections 6. This innovation, previously exclusive to the top-tier OLED evo model (M Series), utilizes a separate Zero Connect Box to transmit high-definition video. The QNED evo is designed to minimize screen disconnection and deliver natural images even in a wireless setup. Additionally, it has earned AMD FreeSync Premium certification. The TV itself requires only a power cord, allowing for more convenient storage of gaming consoles and set-top boxes. The QNED9M is available in three screen sizes (65/75/85-inch) and has an MSRP starting at $2,499.99. LG QNED AI QNED85 MiniLED 4K Smart TV The LG QNED evo AI 4K TV combines cutting-edge technology to create uniquely bright, colourful images. It has a super-fast native 120Hz refresh rate, so viewers see smoother action; plus, Dimming Pro dynamically adjusts the MiniLED back lights to maintain deep black levels, enabling viewers to be fully immersed in content. Users will enjoy outstanding picture powered by the Alpha 8 AI Processor Gen2, which uses AI to detect what's playing and automatically improves the picture and sound quality. Gamers will experience real-time action with virtually no tearing from FreeSync™, VRR and GeForce NOW for cloud gaming 7. Plus, the LG Game Optimizer, Game Dashboard keeps gamers in the action. The QNED85 is available in six screen sizes (50/55/65/75/86 and new100-inch) with an MSRP starting at $1,099.99. _____________________________ 6 Wireless transmission refers to the transferring of video and audio signals between a TV screen and the Zero Connect Box. Visually lossless, based on internal test results with ISO/IEC 29170-2 and measurement results may vary depending on connection status. 7 Subscription and compatible gaming controller are required. LG QNED AI QNED80 4k Smart TV Experience radiant colour and refined detail with the LG QNED80 AI 4K TV. Powered by the α7 AI Processor Gen8, this TV delivers vivid visuals through Dynamic QNED Colour with 100% Colour Volume 5. HDR10 Pro enhances each colour for a dramatic effect, while FILMMAKER MODE™ with Ambient Light compensation adapts to surrounding lighting conditions and keeps visuals as close as possible to the director's original vision. Enjoy LG's webOS smart platform, offering personalized streaming and software updates for up to 5 years. The QNED80 is available in six screen sizes (43/50/55/65/75/86-inch) and has an MSRP starting at $499.99. Lifestyle Solutions LG's lifestyle category delivers premium, adaptable entertainment solutions designed to seamlessly integrate into diverse environments. LG StanbyME 2 Super Portable Touch Screen The LG StanbyME 2 redefines flexible entertainment and productivity with its innovative design and enhanced features. A 2025 iF Design Award Winner, the detachable, portable 27-inch screen offers users different ways to enjoy content: roll the screen around with the adjustable stand; detach it and hang it up; or use it like a tablet with the folio cover. The built-in battery in the rollable stand offers up to 4 hours of battery life 8, enabling users to enjoy content for longer. The screen can be easily charged and connected with the USB-C port and built-in USB and HDMI ports enable easy connection to external devices. Mood Maker transforms the screen into a digital photo frame and enables users to select themes that express their individual style and interests such as clock, weather, turntable and more. The LG StanbyME 2 also offers hands-free convenience with long-distance voice recognition, letting you control your content from across the room. Its versatile adjustability, coupled with its sleek design, makes it a stylish and functional addition to many spaces. The MSRP for the LG StanbyME 2 is $1,599.99. ____________________________ 8 Up to 4 hours wireless use in Eco/Low Power Mode with built-in battery. Battery life may vary by usage. Requires a minimum output of 65W or more for charging. Devices must support USB PD. Availability LG's 2025 TV and Lifestyle media entertainment lineup is now available on and at retailers nationwide. For complete product details and where to buy, visit About LG Electronics Canada Inc. LG Electronics Canada, Inc. is the Canadian subsidiary of LG Electronics Inc., a global sales innovator in technology and manufacturing headquartered in Seoul, South Korea. LG Electronics Canada, with its head office in Toronto, Ontario, is comprised of three business units - Home Appliance Solution, Media Entertainment Solution, and Eco Solution. LG Electronics Canada is focused on delivering award-winning products known for blending style and technology. These innovative products include TVs, audio solutions and portable devices, home appliances, residential and commercial air solutions, computer monitors and laptops, and industry-leading OLED and LED digital display solutions. For more information, visit
